60309-09-3Relevant academic research and scientific papers
USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS
-
Paragraph 00499, (2014/02/16)
no abstract published
CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS
-
Paragraph 00297, (2014/02/16)
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine -γ-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
Synthesis and cardiac imaging of 18F-ligands selective for β1-adrenoreceptors
Radeke, Heike S.,Purohit, Ajay,Harris, Thomas D.,Hanson, Kelley,Jones, Reinaldo,Hu, Carol,Yalamanchili, Padmaja,Hayes, Megan,Yu, Ming,Guaraldi, Mary,Kagan, Mikhail,Azure, Michael,Cdebaca, Michael,Robinson, Simon,Casebier, David
supporting information; experimental part, p. 650 - 655 (2011/11/05)
A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/ β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.
